Effects of Softening Mass Capsule
on Protein in the Urine of
C-BSA-Induced Nephritis Rabbit Models

Chengdu University
of Traditional Chinese Medicine
Chengdu, China

Zhong Baisong, Shi Jingpin, Changke Zhou Xiaopin, Qiu Yu


ABSTRACT:

OBJECTIVE: To investigate the mechanism of the Softening Mass Capsule (SM) in rats with glomerulonephritis and mesangial cells(GMC).
METHODS: (1) The rats with the glomerulonephritis induced by C-BSA were examined with 24h protein of urine and serum albumin test. (2) The thrombocytes, dexamethasone and SM respectively added into cultured GMC were examined with 3H-TdR test.
RESULTS: (1) The 24h protein of urine in trial groups were significantly lower than control group(P= less than 0.05~0.01), and serum albumins were significantly higher than control group(P= less than 0.05~0.01). (2) The GMC in trial groups with thrombocytes were significantly higher than control's (P= less than 0.01), GMC in trial groups with SM, or dexamethasone were significantly lower than control's (P= less than 0.05~0.01).
CONCLUSION: The study revealed SM could reduce 24h protein of urine in rats with glomerulonephritis induced by C-BSA and this effect may correlate with its inhibition of abnormal growth of GMC due to thrombocytes.

KEY WORDS: Softening Mass, Mesangial Cells, Thrombocytes

1. Barnes JL. Platelets in glomerular disease. Nephron. 1997;77(4):378-93.
2. Furness PN. An assessment of the influence of antigen dose in two new models of chronic serum sickness glomerulonephritis in the rat. Br J Exp Path.1987;68:527
6. Arribas I, Rodriguez-Puyol D, Garcia-Escribano MC,et al. Thromboxane A2 and platelet-activating factor decrease in the platelet-mesangial cell interactions. Life Sci 1995;57(10):957-65.
7. Zoja C. Role of platelts in progressive glomerular diseases, Pediatr Nephrol,1995;9:495

  1. Table 1. Effect of SM on 24h Protein of Urine in rats with the glomerulonephritis induced by C-BSA(x±sd)
    Groups-----Dose(mg)------------Protein of Urine(mg/24h)
    ----------------------------------------Pre-trial-----------------Post-trial(2weeks)---------Post-trial(4weeks)
    Control------0.0--------------------6.150±2.26(10)-------8.24±4.10(10)---------------7.11±3.33(10)
    C-BSA-------0.0-----------------101.50±43.10(15)**----28.00±46.20(14)**--------121.90±55.73(10)**
    Endoxan----0.01---------------100.16±36.46(15)**----80.72±65.60(12)??**------53.98±27.76(10)??**
    SM------------8.0----------------100.93±39.44(15)**----75.29 ±33.70(15)??**-----56.35±26.61(10)??**
    SM------------4.0----------------101.15±46.53(15)**----76.25±37.24(15)??**------60.40±(10)32.43??*
    SM------------2.0-----------------99.81±52.07(15)**-----89.54 ±50.95(14)??**-----68.21±22.29(10)??**
    Note: *comparisons with Control P= less than 0.05.
    **comparisons with Control P= less than 0.01.
    ??comparisons with C-BSA P= less than 0.011.

  2. Table 2. Effect of SM on serum albumin in rats with the glomerulonephritis induced by C-BSA
    Groups-----Dose(mg)------------Serum Albumin(mg/L, cases)
    -----------------------------------------Pre-trial-------------Post-trial(2weeks)-------Post-trial(4weeks)
    Control---------0.0-----------------37.15±4.26(10)??-----38.24±2.10(10)**-----37.20±7.19(10)**
    C-BSA----------0.0-----------------33.50±4.10(15)--------30.40±4.20(14)-------21.24±4.73 (10)
    Endoxan-------0.01---------------34.64±2.4(15)----------34.76±3.16(12)*------30.35±3.72(10)**
    SM--------------8.0-----------------33.94±3.4(15)----------37.62 ±4.11(15)**----38.30±12.64(10)**
    SM--------------4.0-----------------32.18±4.5(15)----------35.52±4.24(15)*------29.42±(10)4.25**
    SM--------------2.0-----------------32.83±4.0(15)----------33.75 ±4.59(14)*-----29.74± 3.41(10)**

  3. Table 3. Effect of SM on GMC DNA
    Groups-------------Cases------Dose-------------------CPM-------------Depressed rates( %)
    Control------------------6---------No.II 40µl----------1988.5±153.45--------N/A
    +Dexamethasone----6---------10µg/ml------------1214.2±259.98**-----39.34
    +SM---------------------6---------7.5mg/ml-----------919.2±120.17**------53.77
    +SM---------------------6---------5mg/ml-------------1387.5±82.47**------32.22
    +SM---------------------6---------2.5mg/ml-----------1751.2±290.68------11.93
  4. Table4. Effect of SM on GMC with thrombocyte.
    Groups--------------Cases------Dose------------------CPM-------------Depressed rates( %)
    Control-----------------6----------0µl--------------1988.5±153.45------------N/A
    +Thrombocyte--------6------1.5×106/ml-------3244.3±466.06**-------(-)61.15
    +Dexamethasone----6------10µg/ml-----------1537.7±155.47**?--------52.60
    ++SM-------------------6------7.5mg/ml----------1414.2±80.69**?---------56.41
    ++SM-------------------6------5mg/ml------------1646.8±73.20*?----------49.24
    ++SM-------------------6------2.5mg/ml----------2294.5±91.08*?------
    ----29.28
    Note: ?comparisons with thrombocyte P= less than 0.01

    Journal Overview